Related Experiment Video
Updated: Jun 8, 2026
10:26
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Immunoliposomal systems targeting primary effusion lymphoma: in vitro study.
Barbara Ruozi1, Giovanni Riva, Daniela Belletti
1Department of Pharmaceutical Sciences, University of Modena & Reggio Emilia, Via Campi 183, Modena, Italy. barbara.ruozi@unimo.it
Nanomedicine (London, England)
|September 30, 2010
Summary
Targeted liposomes effectively deliver genes to primary effusion lymphoma (PEL) cells. This novel approach shows promise for treating PEL, a cancer linked to human herpesvirus 8 (HHV8).
Area of Science:
- Biotechnology
- Oncology
- Nanomedicine
Background:
- Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma associated with human herpesvirus 8 (HHV8).
- Effective gene delivery systems are needed to target PEL cells for therapeutic intervention.
Purpose of the Study:
- To develop and evaluate a liposomal formulation for targeted gene delivery against PEL.
- To assess the efficacy of anti-CD138 antibody-conjugated liposomes for gene transfer into PEL cells.
Main Methods:
- Cationic, PEGylated, and anti-CD138 antibody-conjugated liposomes (ILp) were prepared using thin layer evaporation and extrusion.
- Lipoplexes were formed by mixing liposomes with a model oligonucleotide.
- Transfection efficiency was evaluated in BCBL-1 (PEL cell line) using flow cytometry and confocal microscopy.
Main Results:
- ILp demonstrated specific gene delivery to PEL cells, mediated by antigen-antibody interaction.
- A significant increase in transfection rate and localized oligonucleotide internalization was observed with ILp compared to control liposomes.
- Flow cytometry and confocal microscopy confirmed enhanced gene transfer efficacy.
Conclusions:
- ILp serve as effective carriers for oligonucleotide transfer into BCBL-1 cells.
- The in vitro results support further investigation of ILp for in vivo therapeutic applications.
- Targeted liposomes offer a promising strategy for delivering antitumoral agents to PEL.
